- Home
- SCLX vs PHT Comparison
SCLX vs PHT Comparison
Compare SCLX & PHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- PHT
- Stock Information
- Founded
- SCLX 2011
- PHT 2002
- Country
- SCLX United States
- PHT United States
- Employees
- SCLX N/A
- PHT N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- PHT Investment Managers
- Sector
- SCLX Health Care
- PHT Finance
- Exchange
- SCLX Nasdaq
- PHT Nasdaq
- Market Cap
- SCLX 143.6M
- PHT 225.6M
- IPO Year
- SCLX N/A
- PHT N/A
- Fundamental
- Price
- SCLX $1.04
- PHT $7.89
- Analyst Decision
- SCLX Strong Buy
- PHT
- Analyst Count
- SCLX 3
- PHT 0
- Target Price
- SCLX $8.00
- PHT N/A
- AVG Volume (30 Days)
- SCLX 184.3K
- PHT 85.5K
- Earning Date
- SCLX 08-13-2024
- PHT 01-01-0001
- Dividend Yield
- SCLX N/A
- PHT 8.76%
- EPS Growth
- SCLX N/A
- PHT N/A
- EPS
- SCLX N/A
- PHT 0.98
- Revenue
- SCLX $50,833,000.00
- PHT N/A
- Revenue This Year
- SCLX $89.87
- PHT N/A
- Revenue Next Year
- SCLX N/A
- PHT N/A
- P/E Ratio
- SCLX N/A
- PHT $7.71
- Revenue Growth
- SCLX 9.41
- PHT N/A
- 52 Week Low
- SCLX $0.73
- PHT $6.41
- 52 Week High
- SCLX $2.69
- PHT $7.60
- Technical
- Relative Strength Index (RSI)
- SCLX 26.85
- PHT 69.56
- Support Level
- SCLX $1.04
- PHT $7.75
- Resistance Level
- SCLX $1.11
- PHT $7.89
- Average True Range (ATR)
- SCLX 0.08
- PHT 0.05
- MACD
- SCLX 0.00
- PHT 0.01
- Stochastic Oscillator
- SCLX 8.20
- PHT 92.83
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.